Physician profile
Anne Berry Todd
NPI 1346265402
$2,275.53
in general payments reported to CMS, 2019-2025
23 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $200 · 2022: $317 · 2023: $611 · 2024: $389 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $630.93 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $389.94 | 2022-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $299.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $137.89 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $110.25 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $90.71 | 2020-2023 | |
| Pfizer INC. | $86.07 | 2019-2023 | |
| Glaxosmithkline, LLC. | $83.03 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.83 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $46.50 | 2023 | Veozah |
| Amgen INC. | $46.28 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.90 | 2022 | |
| Medtronic Vascular, INC. | $39.29 | 2020 | |
| Amarin Pharma, INC. | $29.19 | 2020 | |
| Novartis Pharmaceuticals Corporation | $28.99 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $25.47 | 2023 | Accrufer |
| Xeris Pharmaceuticals, INC. | $23.35 | 2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $22.78 | 2023 | |
| Shire North American Group INC | $20.79 | 2019 | |
| Merck Sharp & Dohme LLC | $17.89 | 2023 | Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.51 | 2019 | |
| Esperion Therapeutics, INC. | $16.19 | 2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $15.44 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.